October’s top stories: St Jude-Thoratec’s $3.3bn deal, Cardinal buys J&J’s Cordis
St Jude Medical has completed the acquisition of Thoratec for $3.3bn, Cardinal Health has acquired Johnson & Johnson's (J&J) cardiology and endovascular devices business Cordis, for $1.9bn and Pressure BioSciences and FIU partnered to develop new PCT-based rape kit test. Medicaldevice-network.com wraps up key headlines from October.
St Jude Medical completed the acquisition of Thoratec, a developer of mechanical circulatory support (MCS) technology to treat advanced heart failure (HF), for $3.3bn.
Under the deal, which was announced in July, St Jude paid $63.50 per share to Thoratec, which produces the HeartMate II left ventricular assist device (LVAD).
Thoratec also manufactures and markets CentriMag, PediMag/PediVAS, HeartMate 3 and HeartMate PHP.
The acquisition will allow St Jude to expand its portfolio of products for the management and treatment of HF.
US-based healthcare services firm Cardinal Health completed the acquisition of Johnson & Johnson's (J&J) cardiology and endovascular devices business Cordis for $1.9bn.
The acquisition, which was first announced by the companies in March, will expand Cardinal's portfolio of physician preference items, including cardiovascular, wound management, and orthopaedics products.
The company is helping customers standardise medical devices, while providing new solutions in supply chain management, inventory optimisation, work flow tools and data to support effective management of the patient.
US-based Pressure BioSciences (PBI) entered a collaborative research and development agreement with Florida International University (FIU) to develop a new rape kit test method, based on its pressure cycling technology (PCT) platform.
The rape kit test is expected to be commercially available within the next 18 months.
The company noted there is a significant and urgent need for better test methods to address the national issue, as there is a current estimated backlog of 400,000 untested rape kits in the US and an estimated 180,000 new sexual assault cases annually.
Siemens launched an automated quantitative thyroid stimulating immunoglobulin (TSI) assay designed for use in the differential diagnosis of Graves' disease, an autoimmune disorder.
Introduced by Siemens Healthcare Laboratory Diagnostics, the new assay is available on the Siemens Immulite 2000 and Immulite 2000 XPi immunoassay systems.
The TSI assay detects only thyroid stimulating antibodies in Graves' disease, while TRAb (TSH receptor antibody) assays detect both stimulating and blocking antibodies.
Royal Philips entered a partnership with Massachusetts Institute of Technology (MIT) to explore the use of its ultrasound technology and physiological modelling.
The technology is being considered as a less invasive way to measure intracranial pressure (ICP).
ICP is an essential tool for managing patients with brain injuries.
The research could also allow doctors to use the measurement on less critical patients, who might not normally be considered for such monitoring.
Toshiba America Medical Systems, a provider of medical diagnostic imaging systems, expanded its x-ray product portfolio, with the introduction of the new Ultimax-i FPD multipurpose system.
The multipurpose system was developed to conduct complex procedures by providing routine angiography lab capabilities within an existing R&F space.
It is designed to efficiently use the space providers have to safely diagnose and treat all patients, without the need for a major renovation.
Belgium-based Lucimed launched a new light therapy device, Luminette, a portable solution for people suffering from seasonally induced issues.
Currently available in Europe, the light therapy glasses provide relief from seasonal affective disorder (SAD), sleep disorders and circadian rhythm issues such as jet lag and shift work.
Luminette was developed after four years of university research and clinical trials.
US-based medical device firm Rijuven introduced CardioSleeve for paediatrics, the smart ECG stethoscope attachment that enhances cardio-diagnostic processes.
CardioSleeve is the first FDA cleared device that adds ECG capabilities to transform any existing stethoscope into a smart and mobile-connected device, offering three lead ECG, digital auscultation and real-time digital analysis for paediatric care.
Part of the company's i2Dtx platform, CardioSleeve enables paediatricians and clinicians to accurately visualise heart sound, analyse for arrhythmia or murmur and identify heart failure.